Science

Circulating Tumor DNA Clearance as a Predictive Biomarker of Pathologic Complete Response in Solid Tumors Treated with Neoadjuvant ICIs

Photo: depositphotos.com

May 7, 2025, 09:10

Circulating Tumor DNA Clearance as a Predictive Biomarker of Pathologic Complete Response in Solid Tumors Treated with Neoadjuvant ICIs

Dana-Farber’s Breast Oncology Center shared a post on X:

“Check out this recent Annals of Oncology ctDNA review and meta-analysis”

Title: Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis.

Authors: Carmine Valenza, E.F. Saldanha, Y. Gong, Pietro De Placido, David Gritsch, H. Ortiz, Dario Trapani, F. Conforti, C. Cremolini, S. Peters, J. Mateo, V. Subbiah, Heather Parsons, Ann Partridge, Giuseppe Curigliano

You can read the Full Article on ESMO Annals of Oncology.

Tumor DNA

More posts featuring Dana-Farber’s Breast Oncology Center.

Ann Partridge Annals of Oncology Cancer research Carmine Valenza Dana-Farber’s Breast Oncology Center Dario Trapani David Gritsch DNA Giuseppe Curigliano Heather Parsons Immune Checkpoint Inhibitors Pietro De Placido tumor DNA

A Call for Peace from the Frontlines of Pediatric Oncology by the POEM Group

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals

Penn Medicine: Cancer Center Near Me

Elevating Childhood Cancer and Catastrophic Diseases in the Global NCD Agenda: Joint Call to Action

King Hussein Cancer Research Award: Don’t Miss Your Chance to Apply